This is a single-center, single-arm, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib as adjuvant therapy in hepatocellular carcinoma (HCC) participants who are at high risk of recurrence after curative resection.
Voluntarily participate in this study and sign an informed consent form.
Participants diagnosed with HCC through pathological histology/cytology or clinically diagnosed with HCC according to the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition).
Within 4-12 weeks prior to enrollment, radical resection surgery was performed.
Complete recovery from surgical resection within 4 weeks prior to enrollment.
Known hepatobiliary carcinoma, sarcoma like hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma，and fibrous layer cell carcinoma; Within 5 years or simultaneously suffering from other active malignant tumors other than hepatocellular carcinoma (excluding cured skin basal cell carcinoma and cervical carcinoma in situ).
There are uncontrollable extrahepatic metastases, such as lung and brain metastases (EHS).
Previously received local treatment, including therapeutic TACE, transarterial embolization (TAE), hepatic artery infusion chemotherapy (HAIC), transarterial radiation embolization (TARE), etc.
Participants who are preparing to undergo or have previously received organ or allogeneic bone marrow transplantation.
Single group
Adebrelimab + Apatinib
Drugthe first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years
RFS Rate at 12 and 24 Months
Recurrence-free survival rate at 12 and 24 Months
overall survival
Defined as the time from enrollment to death from any cause
Time to Recurrence
The time interval between liver resection and diagnosis of HCC recurrence
recurrence-free survival
Ratio of participants from first treatment to disease recurrence
Click on the lead sponsor to view all of their trials.
